Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 34014249

Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of Dual ERBB2 Blockade in Patients With ERBB2-Positive Breast Cancer: A Secondary Analysis of the TRAIN-2 Randomized, Phase 3 Trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
JAMA Oncol
Publication date
2021 Jul 1
First author
van der Voort A

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    JAMA Oncol. 2021 Jul 1;7(7):975-977. doi: 10.1001/jamaoncol.2021.1314.
    note
    Source null
    related pmid
    34014297
    relationship
    Comment in

Authors and identifiers

  1. name
    van der Voort A
    type
    Author
  2. name
    van Ramshorst MS
    type
    Author
  3. name
    van Werkhoven ED
    type
    Author
  4. name
    Mandjes IA
    type
    Author
  5. name
    Kemper I
    type
    Author
  6. name
    Vulink AJ
    type
    Author
  7. name
    Oving IM
    type
    Author
  8. name
    Honkoop AH
    type
    Author
  9. name
    Tick LW
    type
    Author
  10. name
    van de Wouw AJ
    type
    Author
  11. name
    Mandigers CM
    type
    Author
  12. name
    van Warmerdam LJ
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    van der Voort A
    type
    Author
  2. name
    van Ramshorst MS
    type
    Author
  3. name
    van Werkhoven ED
    type
    Author
  4. name
    Mandjes IA
    type
    Author
  5. name
    Kemper I
    type
    Author
  6. name
    Vulink AJ
    type
    Author
  7. name
    Oving IM
    type
    Author
  8. name
    Honkoop AH
    type
    Author
  9. name
    Tick LW
    type
    Author
  10. name
    van de Wouw AJ
    type
    Author
  11. name
    Mandigers CM
    type
    Author
  12. name
    van Warmerdam LJ
    type
    Author
bibliography ids
  1. nci-bib-3f27207526edb248e04a7e61
book metadata
content sha256
abc8068cdf3c40de9480e55576850ed4f92cd123f7e168e64c15ff66157221e1
document type
citation
dois
  1. 10.1001/jamaoncol.2021.1371
electronic publication date
display
Source null
precision
missing
year
Source null
evidence scope
bibliographic_metadata_only
id
pubmed:34014249
immutable id
pubmed:34014249@abc8068cdf3c40de9480e55576850ed4f92cd123f7e168e64c15ff66157221e1
journal
abbreviation
JAMA Oncol
issn electronic
2374-2445
issn print
2374-2437
issue
7
name
JAMA oncology
nlm unique id
101652861
pages
978-984
volume
7
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    JAMA Oncol. 2021 Jul 1;7(7):975-977. doi: 10.1001/jamaoncol.2021.1314.
    note
    Source null
    related pmid
    34014297
    relationship
    Comment in
outcomes validated
false
pmid
34014249
provenance
batch id
79f1021053e858d13ff3
provider
NCBI PubMed ESummary
record sha256
14c8ed6c207dc4c48d622ba00a9c7c54da35c4136a5d2147e53eae420399686e
response sha256
671d3d2962f73c698a1cb338d73222e2cc6cfdf61569f91b42612d5b59822e05
retrieved at
2026-09-09T23:47:59.098265+00:00
publication date
display
2021 Jul 1
precision
day
year
2021
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Randomized Controlled Trial
  4. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/34014249/
title
Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of Dual ERBB2 Blockade in Patients With ERBB2-Positive Breast Cancer: A Secondary Analysis of the TRAIN-2 Randomized, Phase 3 Trial.

Preserved source evidence · Not medical advice